首页> 外国专利> Method for measuring blood procoagulant activity of human leukocyte antigens

Method for measuring blood procoagulant activity of human leukocyte antigens

机译:测量人白细胞抗原血液促凝活性的方法

摘要

Thromboembolic complications have been documented in cancer patients and mismatched organ transplant recipients. Procoagulants have been implicated in these processes and may play an additional role in tumor metastases. Two proteins displaying procoagulant activity, with molecular weights of 35,000 and 28,000 daltons, were isolated from human ovarian carcinoma extracts. The amino terminal sequence of the first 12 amino acids of the 35,000 dalton protein was determined to be IKEEHVIIQAEF. This sequence displays 100% homology to the major histocompatibility (MHC) antigen HLA-DR which exists as an heterodimer composed of a 35 kDa and 28 kDa protein. The procoagulant activity was further purified through immunoaffinity column chromatography involving a monoclonal antibody to HLA-DR. The immunoaffinity purified protein enhanced thrombin generation in recalcified normal plasma approximately 20-fold. HLA-DR procoagulant activity was completely abrogated by the addition of Staphylcoccal aureus enterotoxin A (SEA).
机译:在癌症患者和不匹配的器官移植接受者中已经记录了血栓栓塞并发症。促凝剂已经牵涉到这些过程中,并且可能在肿瘤转移中起其他作用。从人卵巢癌提取物中分离出两种具有促凝活性的蛋白质,分子量分别为35,000和28,000道尔顿。确定35,000道尔顿蛋白的前12个氨基酸的氨基末端序列为IKEEHVIIQAEF。该序列与主要组织相容性(MHC)抗原HLA-DR具有100%的同源性,后者以35 kDa和28 kDa蛋白质组成的异二聚体形式存在。通过涉及HLA-DR单克隆抗体的免疫亲和柱色谱法进一步纯化促凝活性。免疫亲和纯化蛋白在重新钙化的正常血浆中增强了凝血酶的生成,约为20倍。通过添加金黄色葡萄球菌肠毒素A(SEA),可以完全消除HLA-DR促凝活性。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号